ColinHughes Ph.D.


San Diego + 1.858.314.1120

Colin Hughes prepares and prosecutes patent applications throughout the world to obtain patent protection in areas including biotechnology, chemistry, and pharmaceuticals. He provides clients with a broad range of services, including U.S. and foreign patent portfolio development and management, patentability and validity assessments, freedom to operate analysis, and patent strategy counseling.

He also has experience in post-grant proceedings, including inter partes review (IPR) and interference proceedings before the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office, and opposition procedures before the European Patent Office. He has worked closely with expert witnesses in drafting declarations, designing experiments, and preparing for depositions.

Representative clients include Celgene Corporation and Idenix Pharmaceuticals (now Merck). Pharmaceutical products for which Colin has experience include Revlimid®, Pomalyst®, Otezla®, and Vidaza®.

Prior to practicing law, Colin obtained his Ph.D. in organic chemistry, conducting research in the area of total synthesis of natural products. During this time he performed complex multistep synthesis and prepared hundreds of compounds on scales ranging from milligram quantities up to 200 grams. One result of his research was the completion of the total synthesis of the proposed structure of aldingenin B.


  • Celgene acquired by Bristol-Myers Squibb for approximately $74 billionJones Day advised Celgene Corporation (NASDAQ: CELG) in connection with the intellectual property and technology transactions aspects of its cash-and-stock merger with Bristol-Myers Squibb (NYSE: BMY) which has an equity value of approximately $74 billion.
  • Idenix challenges Gilead's patent rights to Sovaldi® (sofosbuvir)Jones Day represents Idenix Pharmaceuticals LLC (a subsidiary of Merck & Co., Inc.) in patent interference against Gilead.
  • Idenix challenges Gilead's patent rights to methods of treating HCV with Sovaldi® (sofosbuvir)Jones Day represents Idenix Pharmaceuticals LLC (a subsidiary of Merck & Co., Inc.) in a patent interference against Gilead.
  • Celgene develops patent portfolio for use of different polymorphic forms of 5-AZACYTIDINEJones Day assists Celgene Corporation with obtaining patent protection for different polymorphic forms of 5-AZACYTIDINE.
  • Celgene seeks patent protection for different oral formulations of 5-AZACYTIDINEJones Day is prosecuting applications and developing a patent portfolio on behalf of Celgene Corporation for oral formulations of 5-AZACYTIDINE.
  • Celgene appeals decision from Opposition Division to revoke lenalidimide European patentJones Day represents Celgene Corporation in the appeal of a decision in opposition proceedings against two generic companies opposing a Celgene European patent covering the polymorphs of lenalidimide.
  • Celgene establishes global patent portfolio for its brands REVLIMID®, POMALYST®, OTEZLA®, VIDAZA®, ABRAXANE® and ISTODAX®Jones Day assists Celgene Corporation in the establishment of its global patent portfolio related to lenalidomide (REVLIMID®), pomalidomide POMALYST®), apremilast (OTEZLA®), azacitidine (VIDAZA®), ABRAXANE® and romidepsin (ISTODAX®) for the treatments of cancer and immune, inflammatory conditions.
  • Celgene defends patents covering lenalidomide and apremilast before European Patent OfficeJones Day represents Celgene Corporation in defense of patents covering lenalidomide and apremilast against oppositions brought before the European Patent Office by generic pharmaceutical companies.
  • We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.